NYSEAMERICAN:IGC

IGC Pharma Q1 2026 Earnings Results & Report

IGC Pharma logo
$0.19 +0.01 (+7.37%)
Closing price 04:10 PM Eastern
Extended Trading
$0.18 0.00 (-2.08%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IGC Pharma reported Q1 2026 earnings on May 15, 2026. The company reported EPS of -$0.02, while revenue was $317 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
8:00 AM ET

IGC Pharma EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

IGC Pharma Revenue Results

Actual Revenue
$317 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

IGC Pharma Q1 2026 Earnings FAQ

IGC Pharma (NYSEAMERICAN:IGC) reported earnings of -$0.02 per share for Q1 2026. The report was announced on Friday, May 15, 2026.

IGC Pharma reported revenue of $317 thousand for Q1 2026.

IGC Pharma Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More IGC Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IGC Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGC Pharma and other key companies, straight to your email.

About IGC Pharma

IGC Pharma (NYSEAMERICAN:IGC) is a clinical-stage pharmaceutical company developing cannabinoid-based therapies, with a focus on Alzheimer’s disease and other neurological conditions. Its lead program, IGC-AD1, is being studied as a potential treatment for agitation associated with Alzheimer’s disease.

The company was formerly known as India Globalization Capital, reflecting its earlier business activities in India, which included infrastructure and mining. It later shifted its focus to cannabinoid-based drug development and has also been involved in hemp-derived consumer products.

IGC Pharma is headquartered in Potomac, Maryland. Ram Mukunda is the company’s founder and chief executive officer.

View IGC Pharma Profile